公开(公告)号：US20170138931A9

公开(公告)日：2017-05-18

申请号：US12422632

申请日：2009-04-13

申请人： JOHANNES ROTH ,  CLEMENS SORG

发明人： JOHANNES ROTH ,  CLEMENS SORG

IPC分类号： A61K31/4985 ,  A61P29/00

CPC分类号： G01N33/53 ,  C12Q1/6883 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N33/564 ,  G01N33/6893 ,  G01N2333/4727 ,  G01N2333/52 ,  G01N2800/065

摘要： The present invention is directed to a method for diagnosing inflammatory diseases based on the marker CALGRANULIN C, particularly for diagnosing specific stages of inflammatory diseases and/or for determining the risk of relapse and/or for discriminating between diseases with similar symptoms, said method comprising the steps of (a) obtaining a biological sample of mammalian body fluid or tissue to be diagnosed; (b) determining the amount and/or concentration of CALGRANULIN C polypeptide and/or nucleic acids encoding the polypeptide present in said biological sample; and (c) comparing the amount and/or concentration of CALGRANULIN C polypeptide determine in said biological sample with the amount and/or concentration of CALGRANULIN C polypeptide as determined in a control sample and/or comparing the amount and/or concentration of nucleic acids encoding CALGRANULIN C polypeptide determined in said biological sample with the amount and/or concentration of nucleic acids encoding CALGRANULIN C polypeptides measured in a control sample, wherein the difference in the amount of CALGRANULIN C polypeptide and/or nucleic acids encoding the polypeptide is indicative for the stages of the disease to be diagnosed.

公开(公告)号：US20100311758A1

公开(公告)日：2010-12-09

申请号：US12422632

申请日：2009-04-13

申请人： JAHANNES ROTH ,  CLEMENS SORG

发明人： JAHANNES ROTH ,  CLEMENS SORG

IPC分类号： A61K31/4985 ,  A61P29/00

CPC分类号： G01N33/53 ,  C12Q1/6883 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N33/564 ,  G01N33/6893 ,  G01N2333/4727 ,  G01N2333/52 ,  G01N2800/065

摘要： The present invention is directed to a method for diagnosing inflammatory diseases based on the marker CALGRANULIN C, particularly for diagnosing specific stages of inflammatory diseases and/or for determining the risk of relapse and/or for discriminating between diseases with similar symptoms, said method comprising the steps of (a) obtaining a biological sample of mammalian body fluid or tissue to be diagnosed; (b) determining the amount and/or concentration of CALGRANULIN C polypeptide and/or nucleic acids encoding the polypeptide present in said biological sample; and (c) comparing the amount and/or concentration of CALGRANULIN C polypeptide determine in said biological sample with the amount and/or concentration of CALGRANULIN C polypeptide as determined in a control sample and/or comparing the amount and/or concentration of nucleic acids encoding CALGRANULIN C polypeptide determined in said biological sample with the amount and/or concentration of nucleic acids encoding CALGRANULIN C polypeptides measured in a control sample, wherein the difference in the amount of CALGRANULIN C polypeptide and/or nucleic acids encoding the polypeptide is indicative for the stages of the disease to be diagnosed.

摘要翻译： 本发明涉及一种用于诊断基于标记物CALGRANULIN C的炎性疾病的方法，特别是用于诊断炎性疾病的特定阶段和/或用于确定复发的风险和/或用于区分具有相似症状的疾病的所述方法，所述方法包括 （a）获得待诊断的哺乳动物体液或组织的生物样品的步骤; （b）确定所述生物样品中存在的CALGRANULIN C多肽和/或编码多肽的核酸的量和/或浓度; 和（c）将所述生物样品中确定的CALGRANULIN C多肽的量和/或浓度与对照样品中测定的CALGRANULIN C多肽的量和/或浓度进行比较和/或比较核酸的量和/或浓度 编码在所述生物样品中测定的CALGRANULIN C多肽与在对照样品中测量的编码CALGRANULIN C多肽的核酸的量和/或浓度，其中编码该多肽的CALGRANULIN C多肽和/或核酸的量的差异指示 要诊断的疾病的阶段。